Innovation that solves real problems
Purpose-builtEvery tool starts from an operational bottleneck our teams meet on live studies, never technology for its own sake. We automate the repetitive so our experts can focus on the science.
Building the future of
biometrics delivery
We're investing in intelligent tools, automation and AI-assisted workflows that reduce manual effort, improve consistency and help our experts focus where they add the greatest value. Some of these capabilities are already in production, while others are actively being developed and will be introduced as part of our evolving innovation roadmap.
Four principles behind how we innovate
Experts stay in control
Human-ledAI-assisted review, automated checks and intelligent pipelines draft, reconcile and flag. Our biostatisticians, programmers and data managers own every decision.
Validated and inspection-ready
CompliantNew capabilities move from pilot to validated only once they are tested, documented and traceable. Innovation never comes at the cost of quality or compliance.
Faster, more consistent delivery
EfficiencyStandardised, metadata-driven builds and reusable frameworks turn every study into a faster, more repeatable delivery with quality built in from the start.
Tools developed for real study needs
Your clinical data science platform
Alethia is a purpose-built centralized clinical data science platform, enabling users to centralize and discover their data, find insights that lead to faster and better decisions and ultimately better patient outcomes.
MetroDesigner
AI-assisted EDC builds — Drafts an initial eCRF from your study protocol within a couple of hours, ready to upload it to your EDC system, reducing EDC setup timelines to a few weeks.
MetroWriter
AI-assisted CSR authoring — Drafts an initial clinical study report, giving medical writers a structured first draft to review and refine, reducing time to first CSR draft significantly.
MetroSDTM
AI-assisted SDTM aCRF, specification and code generator — Ingest the source data structure and CDISC standards, allowing the user to map the source data to SDTM with recommendations from previous studies and frontier LLMs, in a very efficient user interface.
MetroAnalytics
Clinical Data Analytics Platform — Move away from static Tables, Figures and Listings into the world of interactive visualizations. This R-based visualization system allows study teams to continuously explore their data to find insights, and make timely and accurate decisions.
Agentic Programming Environment
A governed, secure workspace giving programmers safe, controlled access to agentic AI coding tools within a validated environment. Reducing delivery time for programming activities like SDTM, ADaM, TFLs, etc. by more than 30%.
How technology supports delivery
Workflow automation
The repetitive, manual steps automated end to end, so our experts spend their time on judgement.
AI-assisted review
Pattern detection and anomaly flagging that point reviewers to the records that need a human eye.
Quality automation
Edit checks, CDISC validation and reconciliation wired into the workflow — not bolted on before lock.
Reusable frameworks
Validated libraries and templates for datasets, TFLs and submissions that shorten every cycle.
Smart data pipelines
Metadata-driven, CDISC-aligned builds that turn every study into a faster, more repeatable delivery.
Operational insights
Dashboards and signals that surface risk and progress early across the data lifecycle.
Standardisation at scale
Consistent standards applied across studies and programmes for predictable, audit-ready output.
Technology-enabled collaboration
Secure, access-controlled environments that keep everyone working from one source of truth.
„Frontier technologies open the door for Biometrics to reduce time to market by compressing timelines, while maintaining the highest level of quality and providing transparency into the data to stakeholders for faster and better decisions. However, technology alone is not enough, it needs to be combined with domain expertise that can only be acquired through years of experience.”
Questions sponsors ask
When will these tools be available?
Several are already in pilot or validated for internal use; others are in active development. We introduce each capability to client programmes once it is fully validated and inspection-ready — talk to us about your study timeline.
Does AI make the decisions?
No. Our tools assist — drafting, reconciling and flagging — while our biostatisticians, programmers and data managers review and own every output. Technology supports expert judgement; it does not replace it.
Is AI-assisted output validated and compliant?
Every tool follows our control framework: piloted, validated, documented and traceable before it touches a live study. GxP and data-integrity expectations apply throughout.
How is our data kept secure?
Alethia stores clinical data under EntraID authentication with study- and role-level permissions, and our AI workflows run in governed, access-controlled environments. Data security and provenance are designed in from the start.
Can we access these capabilities today?
Some are available for internal delivery now; the wider roadmap is rolling out. We are happy to walk you through what is live, what is in pilot, and what is coming next.